| Autor: |
Varghese NM; a Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund , Jagadguru Sri Shivarathreeswara University , Mysuru , India., Senthil V; a Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund , Jagadguru Sri Shivarathreeswara University , Mysuru , India., Saxena SK; b Centre for Advance Research (CFAR) , King George's Medical University (KGMU) , Lucknow , India. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of drug targeting [J Drug Target] 2018 Mar; Vol. 26 (3), pp. 195-207. Date of Electronic Publication: 2017 Sep 18. |
| DOI: |
10.1080/1061186X.2017.1374389 |
| Abstrakt: |
HIV/AIDS is a global pandemic and the deleterious effects of human immunodeficiency virus in the brain cannot be overlooked. Though the current anti-retro viral therapy is able to reduce the virus load in the peripheral tissues of the body, the inability of the anti-retro viral drugs to cross the blood brain barrier, as such, limits its therapeutic effect in the brain. The development of newer, successful nanoparticulate drug delivery systems to enhance the feasibility of the anti-retro viral drugs to the brain, offers a novel strategy to treat the AIDS-related neuronal degradation. This review summarised the neuropathogenesis of neuroAIDS, the challenges and achievements made in the delivery of therapeutics across the BBB and the use of nanocarriers as a safe and effective way for delivering anti-retro viral drugs to the brain. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
